Definitions of antidepressant treatment response, remission, nonresponse, partial response, and other relevant outcomes: a focus on treatment-resistant depression.
about
Influence of postpartum onset on the course of mood disorders.Pharmacological approaches to the challenge of treatment-resistant depressionAntidepressant effects of the muscarinic cholinergic receptor antagonist scopolamine: a reviewUsing daily monitoring of psychiatric symptoms to evaluate hospital length of stay.Switching from Inadequate Adjunctive or Combination Treatment Options to Brexpiprazole Adjunctive to Antidepressant: An Open-Label Study on the Effects on Depressive Symptoms and Cognitive and Physical Functioning.Antidepressant treatment history as a predictor of response to scopolamine: clinical implications.The Impact of Residual Symptoms in Major DepressionBrief intervention for anxiety in primary care patients.Lower serum brain-derived neurotrophic factor levels are associated with failure to achieve remission in patients with major depression after escitalopram treatmentA randomized, double-blind placebo-controlled trial of oral creatine monohydrate augmentation for enhanced response to a selective serotonin reuptake inhibitor in women with major depressive disorder.A randomized controlled trial of culturally relevant, brief interpersonal psychotherapy for perinatal depression.An open-label, rater-blinded, augmentation study of aripiprazole in treatment-resistant depressionScopolamine produces larger antidepressant and antianxiety effects in women than in men.Mood Disorders in Family Practice: Beyond Unipolarity to BipolarityImprovements in depression and changes in quality of life among HIV-infected adults.Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trialRelationship between amygdala responses to masked faces and mood state and treatment in major depressive disorder.Replication of scopolamine's antidepressant efficacy in major depressive disorder: a randomized, placebo-controlled clinical trialAn Analysis of Relapse Rates and Predictors of Relapse in 2 Randomized, Placebo-Controlled Trials of Desvenlafaxine for Major Depressive Disorder.Minocycline and aspirin in the treatment of bipolar depression: a protocol for a proof-of-concept, randomised, double-blind, placebo-controlled, 2x2 clinical trialImproved Antidepressant Remission in Major Depression via a Pharmacokinetic Pathway Polygene Pharmacogenetic Report.Omega-3 fatty acid augmentation of citalopram treatment for patients with major depressive disorder.Pretreatment Differences in BOLD Response to Emotional Faces Correlate with Antidepressant Response to ScopolamineBaseline mood-state measures as predictors of antidepressant response to scopolamine.Bcl-2 rs956572 polymorphism is associated with increased anterior cingulate cortical glutamate in euthymic bipolar I disorder.A placebo-controlled crossover study of iloperidone augmentation for residual anger and irritability in major depressive disorder.Candidate genes for antidepressant response to selective serotonin reuptake inhibitorsImprovements in Depression and Changes in Fatigue: Results from the SLAM DUNC Depression Treatment Trial.Potential of pretreatment neural activity in the visual cortex during emotional processing to predict treatment response to scopolamine in major depressive disorder.The Illness Density Index (IDI): A longitudinal measure of treatment efficacy.Mechanisms of antidepressant resistanceTreatment goals: response and nonresponseDifferential Peripheral Proteomic Biosignature of Fluoxetine Response in a Mouse Model of Anxiety/Depression.Utility of repetitive transcranial stimulation as an augmenting treatment method in treatment-resistant depression.Transdiagnostic Clinical Global Impression Scoring for Routine Clinical SettingsUtility of repetitive transcranial magnetic stimulation as an augmenting treatment method in treatment-resistant depression.Efficacy and Safety of Transcranial Direct Current Stimulation as an Add-on Treatment for Bipolar Depression: A Randomized Clinical Trial.Antidepressant Outcomes Predicted by Genetic Variation in Corticotropin-Releasing Hormone Binding Protein.Inter and intra-hemispheric structural imaging markers predict depression relapse after electroconvulsive therapy: a multisite study.Functioning outcomes with adjunctive treatments for major depressive disorder: a systematic review of randomized placebo-controlled studies.
P2860
Q25256727-27967020-3BE6-4CE3-ADC6-AAB9C07D7F8FQ26798241-1323A442-ED13-4259-B93C-7BE3C6B3B190Q26822244-BB6FD15D-403B-4BC4-83E7-E3FAD8B42022Q30490331-FC9A5E44-DE43-4A64-A012-1FC1DF5CDD1AQ33625345-E5036116-C4ED-4AD1-B8F8-65F699BFDD96Q33647744-841697EE-57AE-488A-8011-A8E2A6BC469DQ33664080-B67825F6-EDF2-46A3-AF05-2821E67BF9D0Q33957348-6F35116E-CE06-442C-915C-D7B6A5AC994AQ33968773-83F939B4-4DEC-4BE2-9394-F16C3A745ABBQ34292341-69A83084-8392-484F-897E-60E73D8804CBQ34546267-68681AE9-43CE-4E29-81A9-E8459899F65BQ34642676-2F1190F0-51A5-4445-8E36-0145C76EDAB0Q34660507-1F38579F-2199-4BF5-A81F-0767A6199BA1Q35160527-B2493767-A4C8-4279-8B1D-5B25AD848503Q35471815-8F3C901C-9E86-43DF-A99A-377808F98633Q35648180-B59A044F-F147-48FE-8B65-15B8DA2F22E4Q35659957-84384BAF-1AE0-4D2E-844F-BFAE5D28EB4FQ35689739-9FCBD79B-C625-4F74-912D-9ADF32CE8838Q35746646-303A0665-2478-4A27-A7EA-D4B475A1FDBBQ35789318-FC5E2572-81A9-44B0-B1B8-42E19E5DC2A7Q35965584-96A2D8EB-CE99-481E-A8F1-820CA688B0CBQ36034152-F698377E-2488-4C9B-97BB-F775E6940C00Q36064491-71E5BB6F-33DB-4932-A929-4F6509227FC5Q36296905-ADF6037B-D037-41C2-BC5F-DBA32C1106A4Q36540042-C1F1C4D2-DC42-4347-9A1F-DED4E4161688Q36568886-B8CCBB3B-14BD-452C-8EE5-7B7FABB768A3Q36718053-9CCC14CD-E38C-4A9E-9C53-6CBB64DFA6C8Q36998562-447BF7D2-E197-4D5A-96DE-5A42B0BF8CD5Q37029596-B6222C86-B0E4-41B0-A32D-783453BF5DBEQ37091295-F2A97CF9-4C29-44D0-A465-7C608628B0F7Q37334088-9DEE8B8E-86F1-4FD4-907C-CEC051E1822CQ38580554-7EA0169A-A700-4787-8CED-B09F9C351E22Q38634678-6CC0E358-C459-4EFF-93D0-0BA48EE3753FQ38727882-D8665CCF-4082-4F3C-B8B9-540B54A43332Q41663038-4C10126D-635D-4174-AC2B-723C225E74ECQ42122832-8A158011-2611-4948-8370-FCD2D53BC2FFQ47241220-A42DE6CC-B755-46C0-945B-F8CD7281A6DAQ47293332-F3C586D3-DEF5-4482-9B08-BDDC7070B139Q47347879-DE10747B-B5BC-41AF-9DBA-751A17D8B9BEQ47557944-CDAD8917-F70B-4343-A07E-57F2D49BDF04
P2860
Definitions of antidepressant treatment response, remission, nonresponse, partial response, and other relevant outcomes: a focus on treatment-resistant depression.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Definitions of antidepressant ...... reatment-resistant depression.
@ast
Definitions of antidepressant ...... reatment-resistant depression.
@en
Definitions of antidepressant ...... reatment-resistant depression.
@nl
type
label
Definitions of antidepressant ...... reatment-resistant depression.
@ast
Definitions of antidepressant ...... reatment-resistant depression.
@en
Definitions of antidepressant ...... reatment-resistant depression.
@nl
prefLabel
Definitions of antidepressant ...... reatment-resistant depression.
@ast
Definitions of antidepressant ...... reatment-resistant depression.
@en
Definitions of antidepressant ...... reatment-resistant depression.
@nl
P1476
Definitions of antidepressant ...... reatment-resistant depression.
@en
P2093
DeCecco LM
Nierenberg AA
P478
62 Suppl 16
P577
2001-01-01T00:00:00Z